Key result
GDF11 prevented cardiomyocyte hypertrophy induced by testosterone or phenylephrine by modulating Ca2+ signaling and the Smad2/3 pathway.
Why the study?
Does GDF11 prevent cardiomyocyte hypertrophy in neonatal rat cardiomyocytes?
Population
Neonatal rat cardiomyocytes
Comparison
GDF11 pretreatment over 24 h vs Hypertrophic agents alone without GDF11
Design
Preclinical
Follow-up
24 hours
Authors
Loading...
Hypothesis-generating in neonatal rat cardiomyocytes; leaves open translation to human hypertrophy therapies.
Does GDF11 prevent cardiomyocyte hypertrophy in neonatal rat cardiomyocytes?
GDF11 exerts antihypertrophic effects in cardiomyocytes through modulation of IP3-dependent Ca2+ signaling and the Smad2/3 pathway.
Durán et al. (2018) studied Cardiomyocyte hypertrophy. GDF11 vs. Hypertrophic agents (100 nM testosterone or 50 μM phenylephrine) was evaluated on Cardiomyocyte size and [3H]-leucine incorporation. GDF11 prevented cardiomyocyte hypertrophy induced by testosterone or phenylephrine by modulating Ca2+ signaling and the Smad2/3 pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: